Literature DB >> 33644619

First Somatic PRKAR1A Defect Associated With Mosaicism for Another PRKAR1A Mutation in a Patient With Cushing Syndrome.

Crystal D C Kamilaris1, Fabio R Faucz1, Victoria C Andriessen1, Naris Nilubol2, Chyi-Chia Richard Lee3, Mark A Ahlman4, Fady Hannah-Shmouni1, Constantine A Stratakis1.   

Abstract

CONTEXT: Primary pigmented nodular adrenocortical disease (PPNAD) is a rare cause of ACTH-independent Cushing syndrome (CS) associated mostly with Carney complex (CNC), a rare autosomal dominant multiple neoplasia syndrome. More than two-thirds of familial cases and approximately one-third of sporadic cases of CNC harbor germline inactivating PRKAR1A defects. Increasingly sensitive technologies for the detection of genetic defects such as next-generation sequencing (NGS) have further highlighted the importance of mosaicism in human disease. CASE DESCRIPTION: A 33-year-old woman was diagnosed with ACTH-independent CS with abdominal computed tomography showing bilateral micronodular adrenal hyperplasia with a left adrenal adenoma. She underwent left adrenalectomy with pathology demonstrating PPNAD with a 1.5-cm pigmented adenoma. DNA analysis by Sanger sequencing revealed 2 different PRKAR1A variants in the adenoma that were absent from DNA extracted from blood and saliva: c.682C > T and c.974-2A > G. "Deep" NGS revealed that 0.31% of DNA copies extracted from blood and saliva did in fact carry the c.682C > T variant, suggesting low-level mosaicism for this defect.
CONCLUSIONS: We present a case of PPNAD due to low-level mosaicism for a PRKAR1A defect which led to the formation of an adenoma due to a second, adrenal-specific, somatic PRKAR1A mutation. The identification of mosaicism for PRKAR1A, depending on the number and distribution of cells affected has implications for genetic counseling and tumor surveillance. This is the first recorded case of a patient with PRKAR1A mosaicism, PPNAD, and an adenoma forming due to complete inactivation of PRKAR1A in adrenal tissue from a second, somatic-only, PRKAR1A coding sequence mutation. Published by Oxford University Press on behalf of the Endocrine Society 2021.

Entities:  

Keywords:  Carney complex; Cushing syndrome; PRKAR1A; adrenocortical hyperplasia; mosaicism; primary pigmented nodular adrenocortical disease

Year:  2021        PMID: 33644619      PMCID: PMC7885549          DOI: 10.1210/jendso/bvab007

Source DB:  PubMed          Journal:  J Endocr Soc        ISSN: 2472-1972


  36 in total

1.  A six month mitotane course induced sustained correction of hypercortisolism in a young woman with PPNAD and Carney complex.

Authors:  M Cignarelli; G Picca; M Campo; M Margaglione; A Marino; F Logoluso; F Giorgino
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

2.  Deletions of the PRKAR1A locus at 17q24.2-q24.3 in Carney complex: genotype-phenotype correlations and implications for genetic testing.

Authors:  Paraskevi Salpea; Anelia Horvath; Edra London; Fabio R Faucz; Annalisa Vetro; Isaac Levy; Evgenia Gourgari; Andrew Dauber; Ingrid A Holm; Patrick J Morrison; Margaret F Keil; Charalampos Lyssikatos; Eric D Smith; Marc A Sanidad; JoAnn C Kelly; Zunyan Dai; Philip Mowrey; Antonella Forlino; Orsetta Zuffardi; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

3.  Germline deletion and a somatic mutation of the PRKAR1A gene in a Carney complex-related pituitary adenoma.

Authors:  T Iwata; T Tamanaha; R Koezuka; M Tochiya; H Makino; I Kishimoto; N Mizusawa; S Ono; N Inoshita; S Yamada; A Shimatsu; K Yoshimoto
Journal:  Eur J Endocrinol       Date:  2014-10-21       Impact factor: 6.664

4.  Cushing Syndrome in Carney Complex: Clinical, Pathologic, and Molecular Genetic Findings in the 17 Affected Mayo Clinic Patients.

Authors:  Kathleen M Lowe; William F Young; Charalampos Lyssikatos; Constantine A Stratakis; J Aidan Carney
Journal:  Am J Surg Pathol       Date:  2017-02       Impact factor: 6.394

Review 5.  Genetics of micronodular adrenal hyperplasia and Carney complex.

Authors:  Amit Tirosh; Nuria Valdés; Constantine A Stratakis
Journal:  Presse Med       Date:  2018-08-06       Impact factor: 1.228

6.  Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.

Authors:  A H Prowse; A R Webster; F M Richards; S Richard; S Olschwang; F Resche; N A Affara; E R Maher
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

Review 7.  PRKAR1A mutations in primary pigmented nodular adrenocortical disease.

Authors:  Laure Cazabat; Bruno Ragazzon; Lionel Groussin; Jérôme Bertherat
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

8.  Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2.

Authors:  Audrey Robinson-White; Thomas R Hundley; Miriam Shiferaw; Jérôme Bertherat; Fabiano Sandrini; Constantine A Stratakis
Journal:  Hum Mol Genet       Date:  2003-07-01       Impact factor: 6.150

9.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

10.  Fatal Carney Complex in Siblings Due to De Novo Large Gene Deletion.

Authors:  Maria Stelmachowska-Banas; Wojciech Zgliczynski; Piotr Tutka; J Aidan Carney; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2017-11-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.